Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Everolimus
Related studies linked through entity extraction aliases.
Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
- Status
- COMPLETED
- Phase
- PHASE4
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
- Status
- TERMINATED
- Phase
- PHASE2
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
- Status
- WITHDRAWN
- Phase
- PHASE2
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Study of Everolimus (RAD001) in Combination With Lenalidomide
- Status
- COMPLETED
- Phase
- PHASE1
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
- Status
- UNKNOWN
- Phase
- PHASE2
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
- Status
- UNKNOWN
- Phase
- PHASE2
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
- Status
- TERMINATED
- Phase
- PHASE3
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
- Status
- COMPLETED
- Phase
- PHASE1
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE1
An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens
- Status
- COMPLETED
- Phase
- PHASE4
Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE2